Biotech Analysis

In-depth analysis of biotech catalysts, FDA timelines, dilution risk, and market signals — grounded in SEC filings and verified regulatory data.

weekly_roundupNovember 21, 2026

BioTechSign Daily Catalyst Roundup - November 21, 2026

Top BioTechSign catalyst names today: EYPT, MLTX, GRFS, ARGX, NUVB, BBIO. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
weekly_roundupNovember 20, 2026

BioTechSign Daily Catalyst Roundup - November 20, 2026

Top BioTechSign catalyst names today: EYPT, MLTX, GRFS, ARGX, NUVB, BBIO. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
weekly_roundupNovember 19, 2026

BioTechSign Daily Catalyst Roundup - November 19, 2026

Top BioTechSign catalyst names today: EYPT, MLTX, GRFS, NKTR, ARGX, NUVB. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
weekly_roundupNovember 18, 2026

BioTechSign Daily Catalyst Roundup - November 18, 2026

Top BioTechSign catalyst names today: UCBNV, EIKN, ZBIO, CMPX, MLTX, BAYRY. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
weekly_roundupNovember 17, 2026

BioTechSign Daily Catalyst Roundup - November 17, 2026

Top BioTechSign catalyst names today: EYPT, MLTX, VBIO, NKTR, NUVB, BBIO. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
weekly_roundupNovember 16, 2026

BioTechSign Daily Catalyst Roundup - November 16, 2026

Top BioTechSign catalyst names today: BHVN, INO, EYPT, ADCT, SMMT, MLTX. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
weekly_roundupNovember 15, 2026

BioTechSign Daily Catalyst Roundup - November 15, 2026

Top BioTechSign catalyst names today: YMAB, EYPT, SRPT, SMMT, IBRX, IDYA. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
weekly_roundupNovember 14, 2026

BioTechSign Daily Catalyst Roundup - November 14, 2026

Top BioTechSign catalyst names today: EYPT, GRFS, NKTR, ARGX, NUVB, BBIO. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
pdufa_calendarNovember 13, 2026

PDUFA Dates in December 2026: 5 FDA Decisions to Watch

5 FDA PDUFA target dates in December 2026: VNDA Dec 12, CORT Dec 17, MLYS Dec 22, PRAX Dec 27. Every date is sourced to a company SEC filing and verified.

Read analysis →
pdufa_calendarNovember 13, 2026

PDUFA Dates in November 2026: 4 FDA Decisions to Watch

4 FDA PDUFA target dates in November 2026: CAPR Nov 22, BBIO Nov 27, COGT Nov 30, VRTX Nov 30. Every date is sourced to a company SEC filing and verified.

Read analysis →
pdufa_calendarNovember 13, 2026

PDUFA Dates in January 2027: 4 FDA Decisions to Watch

4 FDA PDUFA target dates in January 2027: NUVB Jan 4, IBRX Jan 6, DYN Jan 21, PRAX Jan 29. Every date is sourced to a company SEC filing and verified.

Read analysis →
WWBipoNovember 13, 2026

Windward Bio Prices $175M IPO to Advance China-Licensed Lung Drugs

Windward Bio Group’s approximately $175 million IPO funds WIN378 and WIN027, two respiratory-biologics candidates positioned against the Tezspire market.

Read analysis →
weekly_roundupNovember 12, 2026

BioTechSign Daily Catalyst Roundup - November 12, 2026

Top BioTechSign catalyst names today: KURA, EYPT, GRFS, NKTR, ARGX, NUVB. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
weekly_roundupNovember 11, 2026

BioTechSign Daily Catalyst Roundup - November 11, 2026

Top BioTechSign catalyst names today: UCBNV, KURA, EIKN, ZBIO, CMPX, PBYI. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
weekly_roundupNovember 10, 2026

BioTechSign Daily Catalyst Roundup - November 10, 2026

Top BioTechSign catalyst names today: EYPT, PRAX, NKTR, NUVB, CAPR, BBIO. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
SLSclinical_catalystNovember 9, 2026

SELLAS REGAL Trial Reaches 80th Event: The GPS AML Readout Is Now the Trade

SELLAS reached the 80th event in the Phase 3 REGAL trial of GPS in AML. The milestone unlocks final analysis, but it is not an efficacy result.

Read analysis →
weekly_roundupNovember 8, 2026

BioTechSign Daily Catalyst Roundup - November 08, 2026

Top BioTechSign catalyst names today: ITCI, BGNE, DCPH, SRPT, EYPT, RNA. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
weekly_roundupNovember 7, 2026

BioTechSign Daily Catalyst Roundup - November 07, 2026

Top BioTechSign catalyst names today: KURA, EYPT, SMMT, GRFS, NKTR, ARGX. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
weekly_roundupNovember 6, 2026

BioTechSign Daily Catalyst Roundup - November 06, 2026

Top BioTechSign catalyst names today: EYPT, GRFS, NKTR, ARGX, NUVB, ALNY. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
weekly_roundupNovember 5, 2026

BioTechSign Daily Catalyst Roundup - November 05, 2026

Top BioTechSign catalyst names today: EYPT, SMMT, GRFS, NKTR, ARGX, NUVB. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
GMABmarketNovember 4, 2026

Genmab’s October Phase 3 Run Reprices the Pipeline as Shares Double

Genmab shares doubled in three months after positive Phase 3 readouts for Rina-S, epcoritamab and petosemtamab reshaped investor expectations for its oncology pipeline.

Read analysis →
weekly_roundupNovember 3, 2026

BioTechSign Daily Catalyst Roundup - November 03, 2026

Top BioTechSign catalyst names today: UCBNV, TOI, CMPX, EIKN, ZBIO, INO. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
weekly_roundupNovember 2, 2026

BioTechSign Daily Catalyst Roundup - November 02, 2026

Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
weekly_roundupNovember 1, 2026

BioTechSign Daily Catalyst Roundup - November 01, 2026

Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
weekly_roundupOctober 31, 2026

BioTechSign Daily Catalyst Roundup - October 31, 2026

Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
weekly_roundupOctober 30, 2026

BioTechSign Daily Catalyst Roundup - October 30, 2026

Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
weekly_roundupOctober 29, 2026

BioTechSign Daily Catalyst Roundup - October 29, 2026

Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
weekly_roundupOctober 28, 2026

BioTechSign Daily Catalyst Roundup - October 28, 2026

Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
weekly_roundupOctober 27, 2026

BioTechSign Daily Catalyst Roundup - October 27, 2026

Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
weekly_roundupOctober 26, 2026

BioTechSign Daily Catalyst Roundup - October 26, 2026

Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.

Read analysis →
ROIVclinical_catalystOctober 25, 2026

Roivant’s Positive CLARITY Phase 3 Results: What the Catalyst Changes — and Does Not Change — About Dilution Risk

Roivant reported positive Phase 3 CLARITY results for brepocitinib in non-infectious uveitis. This analysis separates clinical de-risking from financing and dilution risk.

Read analysis →
RCUSpublic_offeringOctober 25, 2026

Arcus Biosciences’ $250 Million Offering: What the Final Share Count Means for Dilution Risk

Arcus Biosciences completed a $250 million base offering and exercised the full underwriter option. Here is the final share count, proceeds, and dilution framework.

Read analysis →
MRNA/PFEfundamental analysisOctober 21, 2026

Understanding the Thesis: The Real Bear Cases for Moderna and Pfizer

A science-first examination of the real bear cases for Moderna and Pfizer: platform economics, oncology execution, patent losses, pipeline replacement, and what investors should actually track.

Read analysis →
NRXPstock analysisOctober 18, 2026

NRXP KETAFREE: November 10 GDUFA Date, FDA Labeling Letter, and 9.8M Shares Short

NRx Pharmaceuticals (NRXP) received an FDA labeling review letter for preservative-free ketamine ahead of a Nov 10 GDUFA date. What's confirmed, short interest data, and dilution risk.

Read analysis →
AZNdeal analysisOctober 15, 2026

AstraZeneca & insitro's $1.5 Billion AI Deal: What It Means for Biotech

AstraZeneca and insitro announced a $1.5 billion AI-enabled target discovery partnership. What the deal structure means, who insitro is, how it fits AstraZeneca's pipeline strategy, and the implications for publicly traded AI drug discovery companies.

Read analysis →
MRNAstock analysisOctober 12, 2026

Moderna's 500% Surge in 2026: What's Actually Driving the MRNA Rocket Ship

Moderna (MRNA) is up more than 500% in 2026 on the back of the first-ever positive Phase 3 result for an mRNA cancer vaccine, Nasdaq-100 index inclusion, and a full narrative reset from pandemic play to oncology platform. Here's what moved the stock and what comes next.

Read analysis →
investor guideOctober 8, 2026

FDA Complete Response Letters: What They Mean and How to Trade Around Them

An FDA Complete Response Letter is a drug rejection that is sometimes not final. Here is how to read a CRL, assess whether resubmission is viable, and understand what the stock does next.

Read analysis →
investor guideOctober 8, 2026

Shelf Registrations and ATM Programs in Biotech: How to Spot Dilution Before It Happens

Shelf registrations and at-the-money offering programs are how most pre-revenue biotechs raise capital. Here is how to read them in SEC filings and use them as dilution risk signals.

Read analysis →
investor guideOctober 8, 2026

How to Read a PDUFA Date: What Every Biotech Investor Needs to Know Before the FDA Deadline

A PDUFA date is the FDA's target deadline to complete review of a new drug application. Here's how to read the filing sequence, what happens at the deadline, and how to use PDUFA dates as an investment signal.

Read analysis →